Alzheimer’s patients given the experimental tau-targeting therapy HMTM in a Phase 3 clinical trial experienced a substantially slower decline in cognitive and functional measures than would be expected based on published research, according to new findings announced by HMTM’s developer TauRx Pharmaceuticals. TauRx expects these results will support applications to gain regulatory approvals of HMTM for treating Alzheimer’s. “The output indicates that participants receiving HMTM decline at a rate substantially less than is typical in…
June 07, 2022June 7, 2022